EGFR and non-small cell lung carcinoma: However, PET detection of new lesions early in the course of therapy has been reported to be a strong, independent predictive factor of OS in NSCLC patients treated by EGFR inhibitor.[27] Our findings are consistent with this observation, as new lesions occurred in 2/8 patients correctly classified as progressive on PET2 and in 4/5 patients correctly classified as progressive on PET3.